Novonesis (Novozymes) B (FRA:NZM) General and Admin. Expense: €225 Mil (TTM As of Mar. 2026)


FRA:NZM Novonesis (Novozymes) B FRA:NZM
90 GF Score
Price €56.50
GF Value €55.83
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Novonesis (Novozymes) B General and Admin. Expense?

Novonesis (Novozymes) B FRA:NZM +0.89% 90 General and Admin. Expense is €225 Mil as of Mar. 2026. GuruFocus rates FRA:NZM with a GF Score™ of 90/100 and a GF Value™ of €55.83 (Fairly Valued). The stock has 6 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Novonesis (Novozymes) B's General and Admin. Expense for the three months ended in Mar. 2026 was €60 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €225 Mil.

Novonesis (Novozymes) B General and Admin. Expense Related Terms

Novonesis (Novozymes) B General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Novonesis (Novozymes) B's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novonesis (Novozymes) B General and Admin. Expense Chart

Novonesis (Novozymes) B Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 115.50 127.77 128.70 214.60 223.20

Novonesis (Novozymes) B Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.30 55.60 54.00 55.30 59.70
FRA:NZM
90GF Score
Novonesis (Novozymes) B FRA:NZM
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novonesis (Novozymes) B General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €225 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of €225 Mil mean?
Novonesis (Novozymes) B (FRA:NZM) has a General and Admin. Expense of €225 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Novonesis (Novozymes) B and its competitors.
Is Novonesis (Novozymes) B's General and Admin. Expense too high?
Novonesis (Novozymes) B's current General and Admin. Expense is €225 Mil. Overall, Novonesis (Novozymes) B has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Novonesis (Novozymes) B's General and Admin. Expense compare to LIN and SHW?
Novonesis (Novozymes) B's General and Admin. Expense of €225 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Chemicals company?
A good General and Admin. Expense depends on the Chemicals industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Novonesis (Novozymes) B and its competitors. Novonesis (Novozymes) B's current General and Admin. Expense is €225 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novonesis (Novozymes) B stock overvalued right now?
Based on GuruFocus' analysis, Novonesis (Novozymes) B (FRA:NZM) is currently considered Fairly Valued. The stock's GF Value™ is €55.83, compared to a current price of €56.50 — trading 1.2% above its estimated fair value. The current General and Admin. Expense is €225 Mil. Novonesis (Novozymes) B's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Novonesis (Novozymes) B (FRA:NZM), the current General and Admin. Expense is €225 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novonesis (Novozymes) B (FRA:NZM) Overvalued in 2026?

Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be overvalued. The current stock price of €56.50 is trading 1.2% above its estimated GF Value™ of €55.83. GuruFocus considers Novonesis (Novozymes) B to be Fairly Valued.

Key valuation signals for FRA:NZM:

  • General and Admin. Expense: €225 Mil
  • GF Value™: €55.83 vs. price of €56.50 (1.2% above fair value)
  • GF Score™: 90/100 with 6 warning signs

No single metric tells the full story. See the FRA:NZM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novonesis (Novozymes) B Business Description

Address Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
90GF Score

Get the complete analysis for FRA:NZM

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€56.50
Price
€55.83
GF Value